Dr. Meghana Raghavendra
Claim this profileFranciscan Health Indianapolis
Area of expertise
Colon Cancer
Meghana Raghavendra has run 5 trials for Colon Cancer. Some of their research focus areas include:
Colorectal Cancer
Meghana Raghavendra has run 3 trials for Colorectal Cancer. Some of their research focus areas include:
Affiliated Hospitals
Franciscan Health Indianapolis
Franciscan Health Mooresville
Clinical Trials Meghana Raghavendra is currently running
Nivolumab + Ipilimumab + Sargramostim
for Advanced Melanoma
This phase II/III trial studies the side effects of nivolumab and ipilimumab when given together with or without sargramostim and to see how well they work in treating patients with stage III-IV melanoma that cannot be removed by surgery (unresectable) and that may have spread from where it first started to nearby tissue, lymph nodes, or distant parts of the body (advanced). Immunotherapy with monoclonal antibodies, such as ipilimumab and nivolumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Colony-stimulating factors, such as sargramostim, may increase the production of white blood cells. It is not yet known whether nivolumab and ipilimumab are more effective with or without sargramostim in treating patients with melanoma.
Recruiting
1 award
Phase 2 & 3
23 criteria
Relatlimab + Nivolumab
for Recurrent Glioblastoma
This phase II trial compares the safety, side effects and effectiveness of anti-lag-3 (relatlimab) and anti-PD-1 blockade (nivolumab) to standard of care lomustine for the treatment of patients with glioblastoma that has come back after a period of improvement (recurrent). Relatlimab is a monoclonal antibody that may interfere with the ability of tumor cells to grow and spread. A monoclonal antibody is a type of protein that can bind to certain targets in the body, such as molecules that cause the body to make an immune response (antigens). Immunotherapy with monoclonal antibodies, such as nivolumab, may help the body's immune system attack the tumor, and may interfere with the ability of tumor cells to grow and spread. Lomustine is a chemotherapy drug and in a class of medications called alkylating agents. It damages the cell's deoxyribonucleic acid and may kill tumor cells. Giving relatlimab and nivolumab may be safe, tolerable, and/or effective compared to standard of care lomustine in treating patients with recurrent glioblastoma.
Recruiting
1 award
Phase 2
15 criteria
More about Meghana Raghavendra
Clinical Trial Related
6 years of experience running clinical trials · Led 13 trials as a Principal Investigator · 2 Active Clinical Trials
Treatments Meghana Raghavendra has experience with
- Nivolumab
- Fluorouracil
- Bevacizumab
- Leucovorin Calcium
- Irinotecan Hydrochloride
- Ipilimumab
Breakdown of trials Meghana Raghavendra has run
Colon Cancer
Colorectal Cancer
Melanoma
Cutaneous Melanoma
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Meghana Raghavendra specialize in?
Meghana Raghavendra focuses on Colon Cancer and Colorectal Cancer. In particular, much of their work with Colon Cancer has involved Stage IV patients, or patients who are Stage III.
Is Meghana Raghavendra currently recruiting for clinical trials?
Yes, Meghana Raghavendra is currently recruiting for 2 clinical trials in Indianapolis Indiana. If you're interested in participating, you should apply.
Are there any treatments that Meghana Raghavendra has studied deeply?
Yes, Meghana Raghavendra has studied treatments such as Nivolumab, Fluorouracil, Bevacizumab.
What is the best way to schedule an appointment with Meghana Raghavendra?
Apply for one of the trials that Meghana Raghavendra is conducting.
What is the office address of Meghana Raghavendra?
The office of Meghana Raghavendra is located at: Franciscan Health Indianapolis, Indianapolis, Indiana 46237 United States. This is the address for their practice at the Franciscan Health Indianapolis.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.